Make intravenous fluids a standard treatment for Dysautonomia

0 have signed. Let’s get to 5,000!

I want to make intravenous fluids a standard treatment for Dysautonomia (e.g. Postural Orthostatic Tachycardia Syndrome and Orthostatic Intolerance) when other treatments have failed. It has changed my life, and I hope it will do the same for others. 

Intravenous fluids (usually saline or Hartmann’s Solution) help increase blood volume, provide extra salts and electrolytes, and redirect nerve signals that all significantly improve the debilitating symptoms of autonomic nervous system dysfunction including fatigue, lightheadedness, palpitations, headache, tinitis, vision loss, syncope, hypotension or hypertension, tachycardia or bracycardia, blood pooling and much more. 

At the moment, intravenous fluids are not yet well recognized as an effective treatment for these conditions, and many patients suffer needlessly on medications or other therapies that are failing to help their symptoms. And over 25% of POTS patients are severely disabled and cannot work, some even permanently wheelchair bound.

IV fluids are the “miracle” treatment for many people and we want doctors to recognize the significant impact to the quality of life that refractory Orthostatic Intolerance and other autonomic disorders has on its patients. These disorders not only impair the way they feel, but also their ability to function in society. With research and treatment, we would hope to see significantly improved outcomes with these people returning to work or school.

Furthermore, fluids are a simple and relatively cheap treatment and most importantly, they are generally effective where other treatments have failed- either long term or for acute exacerbations where the fluids will bring about a speedy resolution and return to baseline.

This petition will be sent to the largest intravenous fluid supply manufacturers in Australia and New Zealand (Baxter). We have already been in contact with their representatives and have been told that if we have the numbers, Baxter will strongly consider funding a large scale research study. This study will not only benefit Australians, but everyone and it will hopefully sway the medical community towards approving and prescribing this treatment.

Here are our goals summarized in three key points:

1. More research

2. Development of clinical guidelines 

3. Patient application

Numbers lead to awareness, and awareness triggers action, research, application and eventually standardization of treatments such as this one. Thank you for your contribution.